Stocks were looking to add to yesterday’s gains this morning. Investor sentiment was boosted by FDA vaccine approval hopes, optimism around the Fed’s Jackson Hole Symposium, and some new signs of policy support in China. Tech shares were higher in early trading.
Notably, as the pandemic led to the practicing of social distancing norms, the demand for robotics and automation increased. Moreover, even after the pandemic, such trends are expected to continue as the rapid shift to digitization maintains its upward trajectory. In fact, Elisabeth Reynold, the executive director of Massachusetts Institute of Technology’s task force on the work of the future, stated that some firms, which have learned to maintain productivity with fewer workers, “will not be willing to unlearn it.”
Automation was already an area of focus before the pandemic. In areas such as manufacturing, robotics has been an integral part of the process. The demand for industrial robotics in automotive and electronics is expanding in 2021. Per a report by Robo Global, by the end of 2021, the installed base of factory robots is estimated to exceed 3.2 million units which will be double the level seen in 2015.
Our stock pick for today highlights a robotics firm that analysts have been steadily raising their estimates for as of late. Find out why in the full article.
Jeff Bezos Just Poured $10 Billion Into This…
Not many people know this story… But in 1998, Bezos invested $250,000 of his own money in Google, when the company was just getting started out of a garage in California. When Google went public in 2004, that $250,000 investment translated into 3.3 million shares of Google stock. Nobody knows if Bezos has sold any shares. If he hasn’t, today they’re worth more than $5.6 billion.Jeff Bezos is betting big on a new trend. This time he’s planning to invest $10 billion of his own money in this exciting new trend. That’s 40,000 times more money than what he invested in Google. That’s how big he thinks this could be. [Full Story…]
Brooks Automation, Inc. (BRKS) provides manufacturing automation solutions for the semiconductor industry and life science sample-based services and solutions for the life sciences market worldwide. Under the Brooks Semiconductor Solutions Group, products include atmospheric and vacuum robots, robotic modules, and tool automation systems that offer precision handling and clean wafer environments, among others. Notably, the robots are well-equipped to handle wafers of all sizes, thin or bonded, and specialized wafer carriers. Further, the robots help in proactive monitoring and upgrading equipment productivity.
BRKS has been getting attention from the analyst community lately. Most recently, the stock was a recipient of a Zacks rating upgrade to Buy. The rating change was triggered by an upward trend in earnings estimates, which is one of the most powerful forces impacting stock prices. An improving earnings picture could translate into buying pressure for BRKS in the near term.
According to Zacks, for the fiscal year ending September 2021, BRKS is expected to earn $2.49 per share, representing an increase of 71.7% from last year. Over the past three months, the Zacks Consensus Estimate for BRKS has increased 24.6%.
The company’s expected earnings growth rate for the current year is 18.6%. If that isn’t reason enough to draw your attention to BRKS stock, consider what the experts have to say. Of five analysts offering recommendations BRKS, 5 rate the stock a Buy, and 3 rate it a Hold. There are no Sell ratings for the stock. A median 12-month price target of $114 represents an increase of 43%.
Where to invest $1,000 right now...
Before you consider buying Brooks Automation, you'll want to see this.
Investing legend, Keith Kohl just revealed his #1 stock for 2022...
And it's not Brooks Automation.
Jeff Bezos, Peter Thiel, and the Rockefellers are betting a colossal nine figures on this tiny company that trades publicly for $5.
Keith say’s he thinks investors will be able to turn a small $50 stake into $150,000.
Find that to be extraordinary?
But you have to act now, because a catalyst coming in a few weeks is set to take this company mainstream... And by then, it could be too late.
New in Biotech:
The Guardian: “New pill could spell the end of all disease.”
This pill is set to completely change the lives of millions of Americans.
And because just one tiny Brisbane company has virtually monopolized this technology with 140 foolproof patents…
Investors who get in on the ground floor stand to become rich beyond their wildest dreams. [Full Story…]